Medicenna Therapeutics Corp (MDNAF)

$0.59 -0.01 (-2.15%)
Market Cap 50.05M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 51,900
Avg Vol 128,934
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 7%
Beta 1.81
Analysts Strong Sell
Price Target $2.96

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15...

Industry: Biotechnology
Sector: Healthcare
Phone: 416-964-5442
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
boomshiva
boomshiva Jul. 20 at 2:01 PM
$MDNAF Jeez louise.
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jul. 13 at 4:51 PM
$MDNAF IMO everything rests on the Neo-Cyt study, do or die. 8 months since an Ability-1 update to me means it’s a bust… and we have zero cash for MDNA-113 I’m hopeful for the neoadjuvent study… if the science on paper plays out in tissue it will be a game changer.
3 · Reply
Pilotboy1985
Pilotboy1985 Jul. 13 at 3:46 PM
$MDNAF increased my position today. I wanted to lower my average since we are hovering at 52 week lows, and I wanted to surpass 20,000 shares. The science is there, the results have been positive, it's just a waiting game but I'm confident we'll be +200% by year end.
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Jul. 13 at 2:47 PM
$MDNAF has a trial in neoadjuvant setting (melanoma) too Noone seems to care... yet... $AGEN
0 · Reply
rudazur2
rudazur2 Jul. 12 at 5:38 PM
$MDNAF 21m marketcap can we see lower ? We have what, 10M$ in cash ?
0 · Reply
Lytnup
Lytnup Jul. 11 at 3:48 PM
$MDNAF Couple of notes while we watch the paint dry. 1). The company is apparently sponsoring this year’s INNOVATE meeting in Naples, to discuss the NEOCYT trial. 2). William Gwynne has accepted the role of Associate Director, Clinical Studies at Medicenna 3). The company filed a Form D on 7/6/26 describing a private placement for roughly $2.34M dated 5-28-26, with just over $250K allocated so far to (3) investors. I am not great at reading these, and SEDAR is down, but I didn’t see pricing, just that it consists of 1 common share and a warrant for 1/2 share (3Y) @ .65. I believe that it’s priced in US dollars. First SEC filing since May 2024. It would seem that things are still happening, albeit at a glacial pace. Best of luck to all MDNAers here - hopefully we hear good news from the fractional CMO on the partnership front.
2 · Reply
OmahaJack
OmahaJack Jul. 8 at 10:41 PM
$MDNAF iIs there hope on the horizon?
2 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jul. 8 at 1:13 AM
$MDNAF Some heavier volume (for us atleast) on both sides of the border… I think something is brewing!
0 · Reply
Lytnup
Lytnup Jul. 7 at 12:05 AM
$MDNAF New Form D - still processing. https://ir.medicenna.com/sec-filings/sec-filing/d/0001807983-26-000003
1 · Reply
NewbJackCity
NewbJackCity Jul. 3 at 3:53 PM
$MDNAF Anyone think we could see 6 week data from NEO-CYT around mid-late July? Not holding my breath. Happy weekend to the brave souls still sticking around 👍🏼
3 · Reply
Latest News on MDNAF
No data available.
boomshiva
boomshiva Jul. 20 at 2:01 PM
$MDNAF Jeez louise.
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jul. 13 at 4:51 PM
$MDNAF IMO everything rests on the Neo-Cyt study, do or die. 8 months since an Ability-1 update to me means it’s a bust… and we have zero cash for MDNA-113 I’m hopeful for the neoadjuvent study… if the science on paper plays out in tissue it will be a game changer.
3 · Reply
Pilotboy1985
Pilotboy1985 Jul. 13 at 3:46 PM
$MDNAF increased my position today. I wanted to lower my average since we are hovering at 52 week lows, and I wanted to surpass 20,000 shares. The science is there, the results have been positive, it's just a waiting game but I'm confident we'll be +200% by year end.
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Jul. 13 at 2:47 PM
$MDNAF has a trial in neoadjuvant setting (melanoma) too Noone seems to care... yet... $AGEN
0 · Reply
rudazur2
rudazur2 Jul. 12 at 5:38 PM
$MDNAF 21m marketcap can we see lower ? We have what, 10M$ in cash ?
0 · Reply
Lytnup
Lytnup Jul. 11 at 3:48 PM
$MDNAF Couple of notes while we watch the paint dry. 1). The company is apparently sponsoring this year’s INNOVATE meeting in Naples, to discuss the NEOCYT trial. 2). William Gwynne has accepted the role of Associate Director, Clinical Studies at Medicenna 3). The company filed a Form D on 7/6/26 describing a private placement for roughly $2.34M dated 5-28-26, with just over $250K allocated so far to (3) investors. I am not great at reading these, and SEDAR is down, but I didn’t see pricing, just that it consists of 1 common share and a warrant for 1/2 share (3Y) @ .65. I believe that it’s priced in US dollars. First SEC filing since May 2024. It would seem that things are still happening, albeit at a glacial pace. Best of luck to all MDNAers here - hopefully we hear good news from the fractional CMO on the partnership front.
2 · Reply
OmahaJack
OmahaJack Jul. 8 at 10:41 PM
$MDNAF iIs there hope on the horizon?
2 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jul. 8 at 1:13 AM
$MDNAF Some heavier volume (for us atleast) on both sides of the border… I think something is brewing!
0 · Reply
Lytnup
Lytnup Jul. 7 at 12:05 AM
$MDNAF New Form D - still processing. https://ir.medicenna.com/sec-filings/sec-filing/d/0001807983-26-000003
1 · Reply
NewbJackCity
NewbJackCity Jul. 3 at 3:53 PM
$MDNAF Anyone think we could see 6 week data from NEO-CYT around mid-late July? Not holding my breath. Happy weekend to the brave souls still sticking around 👍🏼
3 · Reply
boomshiva
boomshiva Jul. 1 at 6:11 PM
$MDNAF It's nice to see a return to $0.30XX, but I'm not holding my breath.
1 · Reply
MarketPulsee
MarketPulsee Jul. 1 at 3:43 PM
Moves like $PNPNF, $VLTLF, and $MDNAF catching strong upside momentum are usually more about thin-liquidity price discovery than any shift in underlying fundamentals. When liquidity is limited and positioning is light, even moderate buy pressure can create sharp vertical moves that look exaggerated compared to large-cap behavior. This is also why microcap segments often appear more “free” in their price action — fewer institutional constraints, less index weighting, and more sensitivity to incremental flow. But that same structure cuts both ways: price discovery works faster in both directions, and reversals can be just as abrupt once momentum fades. The key distinction is that in names like these, price action often leads narrative rather than the other way around.
0 · Reply
bobwut12
bobwut12 Jun. 25 at 2:46 AM
$MDNAF Here's a depressing fact I just noticed, we've done worse YTD than even Briacell ($BCTX ). Canadian biotech penny stocks are rough - I've had multiple go to $0 - hopefully that doesn't happen here
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jun. 24 at 3:25 PM
$MDNAF sad, sp, no news, no planned projected news.. WTF
1 · Reply
boomshiva
boomshiva Jun. 22 at 1:32 PM
$MDNAF Again, and this time right out of the gate!
2 · Reply
steven1x
steven1x Jun. 21 at 12:44 AM
$MDNAF runway https://g.co/gemini/share/0ba90bbabd75
0 · Reply
boomshiva
boomshiva Jun. 16 at 8:33 PM
$MDNAF You're killing me, Smallz!
0 · Reply
Dipper2013
Dipper2013 Jun. 16 at 5:51 PM
$MDNAF wtf..I just came to look..just so disappointed
0 · Reply
AuriniaBeach
AuriniaBeach Jun. 11 at 12:27 PM
$MDNAF Two-pager, forget where I found this. May have been a handout at ASCO.
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jun. 11 at 11:07 AM
$MDNAF patent news but no up dates… https://ir.medicenna.com/news-releases/news-release-details/medicenna-strengthens-us-patent-estate-newly-issued-and-allowed
0 · Reply
TraderBuckNKY
TraderBuckNKY Jun. 3 at 1:34 PM
$MDNAF well, it's something:... NEO-CYT positions MDNA11 in a frontline neoadjuvant melanoma setting, where immunotherapy before surgery may help generate deeper and more durable anti-tumor immune responses Up to 80 patients with locally advanced melanoma will be randomized in this Investigator-sponsored, multicenter Phase 1b NEO-CYT trial led by Professor Paolo A. Ascierto of the Istituto Nazionale Tumori Fondazione “G. Pascale” and sponsored by Fondazione Melanoma Onlus Together with the ongoing Phase 1/2 ABILITY-1 expansion cohorts in the 2L/3L Tx setting, NEO-CYT supports a broader clinical strategy to evaluate MDNA11 across select tumor types and multiple stages of disease, expanding future commercial opportunities MDNA11 clinical data updates from the ABILITY-1 and NEO-CYT trials are anticipated in H2 2026.
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jun. 3 at 11:06 AM
$MDNAF Nothing much to see here folks…. https://ir.medicenna.com/news-releases/news-release-details/medicennas-mdna11-potential-earlier-line-melanoma-setting
1 · Reply